Due to growing demand, ZPD A/S, located on H. E. Bluhmes Vej in Esbjerg, has approved a significant investment in its production of Chondroitin Sulfate for the prevention of osteoarthritis and joint pain. The project aims to enhance ZPD’s production capacity by eliminating current bottlenecks and implementing new production facilities, serving as a catalyst for future growth.
This strategic investment, expected to be installed in 2025, is one of ZPD's largest to date and will open new commercial opportunities. By increasing capacity, the company can better meet rising demand while ensuring the continued delivery of high-quality products.
“This project is a major milestone for ZPD. It will not only improve our supply capabilities and global growth opportunities but also strengthen our position in a growing market where an increasing number of people are being diagnosed with osteoarthritis,” says Kristian Jul Højland, Head of Sales & Business Development at ZPD.
ZPD envisions a world free from the joint pain associated with osteoarthritis, and this investment brings the company closer to that goal. Additionally, the project will create new jobs in Esbjerg, positively contributing to the local community.
For further information, please contact:
Thor Gjelstrup Kronow, Project Manager at ZPD
Phone: +45 20 46 18 08
E-mail: www.tgk@zpd.dk